MX346729B - Compuestos antivirales. - Google Patents
Compuestos antivirales.Info
- Publication number
- MX346729B MX346729B MX2013005575A MX2013005575A MX346729B MX 346729 B MX346729 B MX 346729B MX 2013005575 A MX2013005575 A MX 2013005575A MX 2013005575 A MX2013005575 A MX 2013005575A MX 346729 B MX346729 B MX 346729B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- antiviral compounds
- imidazolylimidazoles
- condensed
- condensed imidazolylimidazoles
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000000840 anti-viral effect Effects 0.000 title abstract 2
- AZUHIVLOSAPWDM-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)-1h-imidazole Chemical class C1=CNC(C=2NC=CN=2)=N1 AZUHIVLOSAPWDM-UHFFFAOYSA-N 0.000 title 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Furan Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La descripción se refiere a compuestos anti-virales, composiciones que contienen tales compuestos, y métodos terapéuticos que incluyen la administración de tales compuestos, así como a procesos e intermediarios útiles para preparar tales compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161560654P | 2011-11-16 | 2011-11-16 | |
PCT/US2012/065681 WO2013075029A1 (en) | 2011-11-16 | 2012-11-16 | Condensed imidazolylimidazoles as antiviral compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013005575A MX2013005575A (es) | 2013-09-05 |
MX346729B true MX346729B (es) | 2017-03-30 |
Family
ID=47324426
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004156A MX361735B (es) | 2011-11-16 | 2012-11-16 | Compuestos antivirales. |
MX2013005575A MX346729B (es) | 2011-11-16 | 2012-11-16 | Compuestos antivirales. |
MX2020010330A MX2020010330A (es) | 2011-11-16 | 2013-05-17 | Proceso para preparar un compuesto antiviral de formula i. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004156A MX361735B (es) | 2011-11-16 | 2012-11-16 | Compuestos antivirales. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010330A MX2020010330A (es) | 2011-11-16 | 2013-05-17 | Proceso para preparar un compuesto antiviral de formula i. |
Country Status (37)
Country | Link |
---|---|
US (14) | US8940718B2 (es) |
EP (4) | EP2907816B1 (es) |
JP (5) | JP6082749B2 (es) |
KR (5) | KR101890400B1 (es) |
CN (2) | CN105837584B (es) |
AP (1) | AP2013006877A0 (es) |
AU (1) | AU2012318253B8 (es) |
BR (1) | BR112013012091A2 (es) |
CA (2) | CA2884712A1 (es) |
CL (1) | CL2013001428A1 (es) |
CO (1) | CO6791562A2 (es) |
CR (1) | CR20130231A (es) |
CY (2) | CY1116987T1 (es) |
DK (2) | DK2635588T3 (es) |
EA (4) | EA030941B1 (es) |
EC (2) | ECSP13012790A (es) |
ES (3) | ES2843023T3 (es) |
HK (1) | HK1188989A1 (es) |
HR (2) | HRP20150725T1 (es) |
HU (2) | HUE039966T2 (es) |
IL (5) | IL226345A (es) |
LT (1) | LT2907816T (es) |
MA (1) | MA34727B1 (es) |
MD (2) | MD4403C1 (es) |
ME (1) | ME02196B (es) |
MX (3) | MX361735B (es) |
MY (1) | MY173045A (es) |
PE (2) | PE20171444A1 (es) |
PH (1) | PH12015502839B1 (es) |
PL (3) | PL2635588T3 (es) |
PT (3) | PT2635588E (es) |
RS (2) | RS57638B1 (es) |
SG (1) | SG10201700947UA (es) |
SI (3) | SI2635588T1 (es) |
SM (1) | SMT201500197B (es) |
UA (2) | UA119437C2 (es) |
WO (1) | WO2013075029A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2345657A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
ME02536B (me) | 2009-05-13 | 2017-02-20 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
SG10201509456SA (en) | 2010-11-17 | 2015-12-30 | Gilead Pharmasset Llc | Antiviral compounds |
JP2014520822A (ja) | 2011-07-09 | 2014-08-25 | スンシネ ルアケ プハルマ カンパニー リミテッド | C型肝炎ウイルス阻害剤としてのスピロ化合物 |
MX354958B (es) | 2011-09-16 | 2018-03-27 | Gilead Pharmasset Llc | Metodos para el tratamiento de vhc. |
RS57638B1 (sr) | 2011-11-16 | 2018-11-30 | Gilead Pharmasset Llc | Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
JP5614568B1 (ja) | 2013-02-07 | 2014-10-29 | 保土谷化学工業株式会社 | ジアザトリフェニレン環構造を有する化合物および有機エレクトロルミネッセンス素子 |
US20140343008A1 (en) * | 2013-05-16 | 2014-11-20 | Gilead Pharmasset Llc | Hepatitis c treatment |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
ES2680550T3 (es) * | 2013-07-09 | 2018-09-10 | Bristol-Myers Squibb Company | Combinaciones de inhibidores del virus de la hepatitis C |
CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
CN104418784B (zh) * | 2013-09-04 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种抗病毒药物中间体的拆分方法 |
WO2015100144A1 (en) | 2013-12-23 | 2015-07-02 | Gilead Sciences, Inc. | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
TW202014413A (zh) * | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
EP3939985B1 (en) | 2014-12-26 | 2024-05-08 | Emory University | Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections |
CN110372559A (zh) * | 2014-12-29 | 2019-10-25 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法 |
CN104586802B (zh) * | 2015-02-02 | 2018-01-16 | 长春海悦药业股份有限公司 | 一种含有索菲布韦的药物组合物 |
CN106008552B (zh) * | 2015-03-01 | 2020-08-21 | 南京圣和药业股份有限公司 | 苯并[e]吡唑并[1,5-c][1,3]噁嗪类化合物及其应用 |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10487067B2 (en) * | 2015-10-08 | 2019-11-26 | Mylan Laboratories Limited | Process for the preparation of velpatasvir |
CN105294713A (zh) * | 2015-10-09 | 2016-02-03 | 重庆康施恩化工有限公司 | Velpatasvir中间体及其制备方法 |
CN105801553B (zh) * | 2016-04-12 | 2018-06-19 | 爱斯特(成都)生物制药股份有限公司 | 一种苯并色烯衍生物的制备方法 |
CN106916134B (zh) * | 2016-04-14 | 2020-04-17 | 苏州楚凯药业有限公司 | 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法 |
WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
EP3452038B1 (en) * | 2016-05-05 | 2022-07-06 | Laurus Labs Limited | Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
AU2017271990B2 (en) | 2016-05-27 | 2019-12-19 | Gilead Sciences, Inc. | Methods for treating Hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors |
BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
WO2018006811A1 (zh) * | 2016-07-08 | 2018-01-11 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的咪唑基化合物及其药物组合物 |
KR101887969B1 (ko) * | 2016-08-30 | 2018-08-13 | 한국과학기술연구원 | 항바이러스 활성을 가지는 카르바졸 화합물 |
CN110698489B (zh) * | 2016-11-30 | 2022-02-22 | 上海新礼泰药业有限公司 | 维帕他韦中间体、制备方法及应用 |
CN106831737B (zh) * | 2017-02-27 | 2020-03-17 | 上海众强药业有限公司 | 维帕他韦及其衍生物的制备 |
CN107501280A (zh) * | 2017-09-05 | 2017-12-22 | 安徽华昌高科药业有限公司 | 一种维帕他韦的合成方法 |
CN107655986B (zh) * | 2017-09-08 | 2020-11-03 | 安徽一灵药业有限公司 | 一种维帕他韦有关物质的检测方法 |
US10849960B2 (en) | 2017-09-08 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer |
KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
CN108276421B (zh) * | 2018-02-13 | 2019-08-06 | 浙江永太药业有限公司 | 一种维帕他韦的合成方法 |
US11865108B2 (en) | 2019-10-18 | 2024-01-09 | Wockhardt Limited | Nitrogen containing bicyclic compounds |
CN111018870B (zh) * | 2019-11-29 | 2021-07-23 | 南京正济医药研究有限公司 | 一种维帕他韦中间体的制备方法 |
CN110981879B (zh) * | 2019-12-09 | 2021-03-05 | 南通常佑药业科技有限公司 | 一种制备ns5a抑制剂-维帕他韦的方法 |
CN113072615B (zh) * | 2021-03-24 | 2023-01-10 | 上海法默生物科技有限公司 | 一种维帕他韦中间体的制备方法 |
CA3220903A1 (en) * | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
EP0533833B1 (en) | 1990-06-13 | 1995-12-20 | GLAZIER, Arnold | Phosphorous produgs |
DE69129650T2 (de) | 1990-09-14 | 1999-03-25 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha | Wirkstoffvorläufer von Phosphonaten |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
DK1625154T3 (da) | 2003-05-09 | 2014-02-24 | Boehringer Ingelheim Int | Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme |
US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
EA200700336A1 (ru) | 2004-07-16 | 2009-12-30 | Джилид Сайэнс, Инк. | Противовирусные соединения |
US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2823981C (en) | 2006-12-07 | 2016-05-17 | Daiichi Sankyo Company, Limited | Film-coated preparation having improved stability |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009102620A2 (en) * | 2008-02-11 | 2009-08-20 | Qualcomm Mems Technologies Inc. | Methods for measurement and characterization of interferometric modulators |
PL2250163T3 (pl) | 2008-02-12 | 2012-10-31 | Bristol Myers Squibb Co | Inhibitory wirusa zapalenia wątroby typu C |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2010008863A (es) | 2008-02-13 | 2010-09-07 | Bristol Myers Squibb Co | Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c. |
US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US8729077B2 (en) * | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
EA201190007A1 (ru) | 2008-12-03 | 2012-06-29 | Пресидио Фармасьютикалс, Инк. | Ингибиторы ns5a вгс |
WO2010096777A1 (en) * | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
KR101411889B1 (ko) | 2009-02-27 | 2014-06-27 | 이난타 파마슈티칼스, 인코포레이티드 | C형 간염 바이러스 억제제 |
WO2010111673A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
CN102427726B (zh) | 2009-03-27 | 2014-10-08 | 普雷西迪奥制药公司 | 丙型肝炎的稠环抑制剂 |
CA2760205A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
ME02536B (me) * | 2009-05-13 | 2017-02-20 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ597982A (en) * | 2009-09-04 | 2013-01-25 | Glaxosmithkline Llc | CHEMICAL COMPOUNDS for treating Hepatitis C virus |
EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
AU2010324871A1 (en) * | 2009-11-25 | 2012-06-14 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102791687B (zh) * | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
US20130156731A1 (en) * | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
MX2012010392A (es) | 2010-03-09 | 2012-10-03 | Merck Sharp & Dohme | Compuesto de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales. |
US9125904B1 (en) | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
WO2011146401A1 (en) | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
BR112013004520A2 (pt) | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
SG10201509456SA (en) | 2010-11-17 | 2015-12-30 | Gilead Pharmasset Llc | Antiviral compounds |
WO2012087976A2 (en) | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
RS57638B1 (sr) | 2011-11-16 | 2018-11-30 | Gilead Pharmasset Llc | Kondenzovani imidazolilimidazoli kao antiviralna jedinjenja |
CA2857339C (en) | 2011-12-29 | 2015-11-17 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
TW202014413A (zh) | 2014-06-11 | 2020-04-16 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
-
2012
- 2012-11-16 RS RS20181062A patent/RS57638B1/sr unknown
- 2012-11-16 DK DK12798525.7T patent/DK2635588T3/en active
- 2012-11-16 UA UAA201507807A patent/UA119437C2/uk unknown
- 2012-11-16 BR BR112013012091A patent/BR112013012091A2/pt not_active Application Discontinuation
- 2012-11-16 UA UAA201306068A patent/UA110354C2/uk unknown
- 2012-11-16 KR KR1020137015198A patent/KR101890400B1/ko active IP Right Grant
- 2012-11-16 MD MDA20130029A patent/MD4403C1/ro active IP Right Grant
- 2012-11-16 PE PE2017001319A patent/PE20171444A1/es unknown
- 2012-11-16 PT PT127985257T patent/PT2635588E/pt unknown
- 2012-11-16 AP AP2013006877A patent/AP2013006877A0/xx unknown
- 2012-11-16 MY MYPI2014001415A patent/MY173045A/en unknown
- 2012-11-16 KR KR1020217010778A patent/KR20210043734A/ko not_active Application Discontinuation
- 2012-11-16 EP EP15156617.1A patent/EP2907816B1/en active Active
- 2012-11-16 CN CN201610126299.4A patent/CN105837584B/zh active Active
- 2012-11-16 KR KR1020187023418A patent/KR102036469B1/ko active IP Right Grant
- 2012-11-16 MD MDA20150091A patent/MD4521C1/ro active IP Right Grant
- 2012-11-16 CA CA 2884712 patent/CA2884712A1/en not_active Abandoned
- 2012-11-16 PT PT181754003T patent/PT3431477T/pt unknown
- 2012-11-16 US US13/679,874 patent/US8940718B2/en active Active
- 2012-11-16 CA CA2815082A patent/CA2815082C/en active Active
- 2012-11-16 SG SG10201700947UA patent/SG10201700947UA/en unknown
- 2012-11-16 CN CN201280004097.2A patent/CN103328480B/zh active Active
- 2012-11-16 RS RS20150571A patent/RS54207B1/en unknown
- 2012-11-16 EA EA201591244A patent/EA030941B1/ru unknown
- 2012-11-16 ES ES18175400T patent/ES2843023T3/es active Active
- 2012-11-16 SI SI201230240T patent/SI2635588T1/sl unknown
- 2012-11-16 PE PE2013001207A patent/PE20141163A1/es active IP Right Grant
- 2012-11-16 HU HUE15156617A patent/HUE039966T2/hu unknown
- 2012-11-16 ES ES15156617.1T patent/ES2687291T3/es active Active
- 2012-11-16 ES ES12798525.7T patent/ES2544107T3/es active Active
- 2012-11-16 ME MEP-2015-132A patent/ME02196B/me unknown
- 2012-11-16 PT PT15156617T patent/PT2907816T/pt unknown
- 2012-11-16 EP EP20194823.9A patent/EP3778606A3/en not_active Withdrawn
- 2012-11-16 KR KR1020207027928A patent/KR102241651B1/ko active IP Right Grant
- 2012-11-16 PL PL12798525T patent/PL2635588T3/pl unknown
- 2012-11-16 WO PCT/US2012/065681 patent/WO2013075029A1/en active Application Filing
- 2012-11-16 MX MX2017004156A patent/MX361735B/es unknown
- 2012-11-16 HU HUE12798525A patent/HUE027733T2/en unknown
- 2012-11-16 EA EA201890333A patent/EA037883B1/ru unknown
- 2012-11-16 US US13/679,862 patent/US20130164260A1/en not_active Abandoned
- 2012-11-16 MX MX2013005575A patent/MX346729B/es active IP Right Grant
- 2012-11-16 LT LTEP15156617.1T patent/LT2907816T/lt unknown
- 2012-11-16 JP JP2014542523A patent/JP6082749B2/ja active Active
- 2012-11-16 EA EA201390576A patent/EA023644B1/ru active Protection Beyond IP Right Term
- 2012-11-16 PL PL15156617T patent/PL2907816T3/pl unknown
- 2012-11-16 EP EP12798525.7A patent/EP2635588B1/en active Active
- 2012-11-16 EA EA202190619A patent/EA202190619A1/ru unknown
- 2012-11-16 EP EP18175400.3A patent/EP3431477B1/en active Active
- 2012-11-16 KR KR1020197030548A patent/KR20190121406A/ko not_active Application Discontinuation
- 2012-11-16 DK DK15156617.1T patent/DK2907816T3/en active
- 2012-11-16 SI SI201231853T patent/SI3431477T1/sl unknown
- 2012-11-16 SI SI201231367T patent/SI2907816T1/sl unknown
- 2012-11-16 AU AU2012318253A patent/AU2012318253B8/en active Active
- 2012-11-16 PL PL18175400T patent/PL3431477T3/pl unknown
-
2013
- 2013-03-01 US US13/783,056 patent/US8575135B2/en active Active
- 2013-05-13 IL IL226345A patent/IL226345A/en active IP Right Grant
- 2013-05-17 CR CR20130231A patent/CR20130231A/es unknown
- 2013-05-17 CO CO13122291A patent/CO6791562A2/es active IP Right Grant
- 2013-05-17 MX MX2020010330A patent/MX2020010330A/es unknown
- 2013-05-17 CL CL2013001428A patent/CL2013001428A1/es unknown
- 2013-06-10 MA MA36000A patent/MA34727B1/fr unknown
- 2013-07-25 EC ECSP13012790 patent/ECSP13012790A/es unknown
- 2013-10-08 US US14/049,133 patent/US8921341B2/en active Active
-
2014
- 2014-02-27 HK HK14101916.3A patent/HK1188989A1/xx unknown
- 2014-04-24 US US14/261,325 patent/US9051340B2/en active Active
- 2014-11-13 US US14/541,057 patent/US9868745B2/en active Active
-
2015
- 2015-04-24 US US14/696,233 patent/US9221833B2/en active Active
- 2015-07-03 HR HRP20150725TT patent/HRP20150725T1/hr unknown
- 2015-08-13 SM SM201500197T patent/SMT201500197B/xx unknown
- 2015-09-09 CY CY20151100779T patent/CY1116987T1/el unknown
- 2015-11-23 US US14/949,756 patent/US20160083394A1/en not_active Abandoned
- 2015-12-21 PH PH12015502839A patent/PH12015502839B1/en unknown
-
2016
- 2016-02-15 IL IL244122A patent/IL244122A0/en unknown
- 2016-02-15 IL IL244124A patent/IL244124A0/en unknown
- 2016-02-15 IL IL244123A patent/IL244123A0/en unknown
- 2016-07-11 US US15/207,415 patent/US9809600B2/en active Active
- 2016-09-02 JP JP2016171840A patent/JP2016199593A/ja not_active Withdrawn
-
2017
- 2017-05-17 IL IL252345A patent/IL252345B/en unknown
- 2017-10-04 US US15/725,193 patent/US20180244683A1/en not_active Abandoned
- 2017-11-15 JP JP2017220056A patent/JP2018024705A/ja not_active Withdrawn
- 2017-11-30 US US15/828,377 patent/US20180186806A1/en not_active Abandoned
-
2018
- 2018-06-27 EC ECSENADI201848718A patent/ECSP18048718A/es unknown
- 2018-08-29 HR HRP20181384TT patent/HRP20181384T1/hr unknown
- 2018-09-12 CY CY20181100945T patent/CY1121225T1/el unknown
- 2018-10-11 US US16/158,204 patent/US10807990B2/en active Active
-
2019
- 2019-04-08 US US16/378,089 patent/US20200071337A1/en not_active Abandoned
- 2019-09-12 JP JP2019166343A patent/JP2019206597A/ja not_active Ceased
-
2020
- 2020-07-24 US US16/938,767 patent/US20210053981A1/en not_active Abandoned
- 2020-10-06 JP JP2020169195A patent/JP2021001230A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502839A1 (en) | Antiviral compounds | |
SG190785A1 (en) | Antiviral compounds | |
MX2020011251A (es) | Compuestos antivirales. | |
MX2014013660A (es) | Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b. | |
MX2009013830A (es) | Compuestos antivirales. | |
MX2009013827A (es) | Compuestos antivirales. | |
CR20150370A (es) | Compuestos antivirales | |
IN2014MN02496A (es) | ||
MX2013015147A (es) | Procesos y compuestos intermediarios para producir azaindoles. | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
IN2015DN00085A (es) | ||
NZ726343A (en) | Antiviral compounds | |
MX2014002378A (es) | Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma. | |
NZ725365A (en) | Antiviral compounds inhibitors of hcv ns5b | |
UA98333C2 (en) | Antiviral compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |